Celldex Therapeutics, Inc. (CLDX) Earnings History
Annual and quarterly earnings data from 1987 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 100.0% | -19160.0% | -17253.3% |
| 2024 | -2229.8% | -2778.9% | -2248.8% |
| 2023 | -1614.5% | -2245.3% | -2054.8% |
| 2022 | -3389.9% | -4889.0% | -4765.6% |
| 2021 | -1046.2% | -1531.8% | -1516.0% |
Download Data
Export CLDX earnings history in CSV or JSON format
Free sign-in required to download data
Celldex Therapeutics, Inc. (CLDX) Earnings Overview
As of February 28, 2026, Celldex Therapeutics, Inc. (CLDX) reported trailing twelve-month net income of -$259M, reflecting -0.6% year-over-year growth. The company earned $-3.89 per diluted share over the past four quarters, with a net profit margin of -172.5%.
Looking at the long-term picture, CLDX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 1989.
Celldex Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including REGN ($4.50B net income, 0.3% margin), CNTA (-$243M net income), IMNM (-$223M net income, -32.4% margin), CLDX has room to improve margins relative to the peer group. Compare CLDX vs REGN →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
39 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$259M | -63.9% | -$287M | $-3.90 | -17253.3% | -19160.0% |
| 2024 | -$158M | -11.6% | -$195M | $-2.45 | -2248.8% | -2778.9% |
| 2023 | -$141M | -25.9% | -$155M | $-2.92 | -2054.8% | -2245.3% |
| 2022 | -$112M | -59.3% | -$115M | $-2.40 | -4765.6% | -4889.0% |
| 2021 | -$71M | -18.0% | -$71M | $-1.64 | -1516.0% | -1531.8% |
| 2020 | -$60M | -17.5% | -$63M | $-2.02 | -805.9% | -854.1% |
| 2019 | -$51M | +66.3% | -$55M | $-3.51 | -1424.0% | -1540.2% |
| 2018 | -$151M | -62.5% | -$156M | $-14.48 | -1585.1% | -1640.1% |
| 2017 | -$93M | +27.6% | -$122M | $-10.86 | -730.1% | -953.7% |
| 2016 | -$129M | -1.0% | -$133M | $-18.99 | -1894.0% | -1958.7% |
See CLDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLDX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CLDX vs AGIO
See how CLDX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CLDX growing earnings?
CLDX EPS of $-3.89 reflects slowing growth at -0.6%, below the 5-year CAGR of N/A. TTM net income is $-259M. Expansion rate has moderated.
What are CLDX's profit margins?
Celldex Therapeutics, Inc. net margin is -172.5%, with operating margin at -191.6%. Below-average margins reflect competitive or cost pressures.
How consistent are CLDX's earnings?
CLDX earnings data spans 1987-2025. The current earnings trend is -0.6% YoY. Historical data enables comparison across business cycles.